Soligenix, Inc. (SNGX)
SNGXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.3427
+0.0087 (+2.60%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $7.41m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.2800 to $1.70
- Average volume
- 163.9k
- Previous close
- $0.3340
Earnings
next estimate $-0.1000Next report
Mar 2026
+6.7%
Jun 2026
+45.5%
Sep 2026
+58.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$2.58m | -$3.48m | -$2.88m | -$2.10m |
| Net income | -$2.53m | -$2.90m | -$2.83m | -$1.99m |
News
8 latest- Pre-Market Movers: PMI, CNTB, RNAZ Chart The Course RTTNews · Jun 3, 2026
- Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX RTTNews · May 28, 2026
- Soligenix Thermostable Platform Shows Promise For Bundibugyo Virus Vaccine; Stock Up RTTNews · May 27, 2026
- Weekly Buzz: FDA Okays Saphnelo Pen, EC Clears Acromegaly Drug, SNGX Slumps, LGND Snaps Up XOMA RTTNews · Apr 30, 2026
- Soligenix Shares Plunge After Phase 3 FLASH2 HyBryte Trial In CTCL Halts For Futility RTTNews · Apr 28, 2026
- Soligenix Gets Positive EMA Opinion For Orphan Drug Status Of SGX945 RTTNews · Feb 26, 2026
- Soligenix Prices 7.5 Mln Public Offering At $1.35/shr; Stock Up In Pre-market RTTNews · Sep 26, 2025
- Why Soligenix Is Rising In Pre-market? RTTNews · Aug 18, 2025
The company
Soligenix is a biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing synthetic hypericin for the treatment of psoriasis (SGX302), and our first-in-class Innate Defense Regulator (IDR) technology, dusquetide, for the treatment of inflammatory diseases, including aphthous ulcers in Behçet's Disease (BD) (SGX945) and oral mucositis in head and neck cancer (SGX942). We were developing HyBryte (SGX301 or synthetic hypericin sodium), a photodynamic therapy utilizing visible light, for the treatment of cutaneous T-cell lymphoma (CTCL) in a Phase 3 study called 'FLASH2' (Fluorescent Light Activated Synthetic Hypericin 2). The Data Monitoring Committee completed its interim efficacy analysis of the FLASH2 trial during April 2026, and under the terms of the interim analysis, the study was recommended to halt for futility.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- soligenix.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.